Skip to content
DataLookout
Menu

UH3NCT05995535

Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal

StatusTerminated
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 6 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial terminated Sponsor's reason: mid analysis showed futility Show 5 more changesShow less
    • Start date: Jan 1, 2024 to Sep 1, 2024
    • Eligibility criteria expanded, about 28 words
    • Final enrollment: 112 participants (planned 150)
    • Interventions: LFX/PGB (Drug), LFX/PLA-PGB (Drug) to LFX/PGB (Drug), LFX/PLA-PGB (Drug)
    • Site details revised at 2 of 2 sites
  2. Minor Site contacts updated at 2 of 2 sitesv6
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 2
    v5
  4. Notable Start date: Nov 1, 2023 to Jan 1, 2024v4
  5. Notable Start date: Sep 1, 2023 to Nov 1, 2023v3
  6. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Subjective Opioid Withdrawal Scale (SOWS) scores
Timeframe: 10 days per subject, through study completion (N=150)

Secondary (2)

Study detox completion
XR-NTX IM injection

Arms and interventions

LFX/PGBExperimental

PGB/day 1=400mg, day 2-7=600mg each day, day 8=400mg, day 9=200mg, day 10=100mg LFX/day 1=1.62mg, day 2-7=2.16mg each day, day 8=1.44mg, day 9=0.72mg, day 10=0.72mg

LFX/PLA-PGBActive comparator

PLA-PGB/day 1-7= 0mg each day, day 8, 9, and 10 =0mg each day LFX/ day 1=1.62mg, day 2-7=2.16mg each day, day 8=1.44mg, day 9=0.72mg, day 10=0.72mg

Drugs: LFX/PGB, LFX/PLA-PGB

Sites

2 sites in 1 country